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Engagement of tumor necrosis factor receptor 1
signals two diametrically opposed pathways:
survival-inflammation and cell death. An additional
switch decides, depending on the cellular context,
between caspase-dependent apoptosis and RIP
kinase (RIPK)-mediated necrosis, also termed nec-
roptosis. We explored the contribution of both cell
death pathways in TNF-induced systemic inflamma-
tory response syndrome (SIRS). Deletion of apoptotic
executioner caspases (caspase-3 or -7) or inflamma-
tory caspase-1 had no impact on lethal SIRS. How-
ever, deletion of RIPK3 conferred complete protec-
tion against lethal SIRS and reduced the amounts of
circulating damage-associated molecular patterns.
Pretreatmentwith theRIPK1 kinase inhibitor, necros-
tatin-1, provided a similar effect. These results sug-
gest that RIPK1-RIPK3-mediated cellular damage
by necrosis drives mortality during TNF-induced
SIRS. RIPK3 deficiency also protected against cecal
ligation and puncture, underscoring the clinical rele-
vance of RIPK kinase inhibition in sepsis and identi-
fying components of the necroptotic pathway that
are potential therapeutic targets for treatment of
SIRS and sepsis.
INTRODUCTION
Tumor necrosis factor (TNF) is a pleiotropic cytokine with func-
tions in immune responses, inflammation, cell survival, and cell
death (Wilson et al., 2009). Two TNF receptors have been iden-
tified, but the diverse functions of TNF are mainly mediated by
TNF receptor 1 (TNFR1), which is expressed on most cell types.
In contrast, TNFR2 is primarily expressed on hematopoietic and
endothelial cells, but its function remains largely unknown
(Faustman and Davis, 2010). Engagement of TNFR1 by TNF
leads to the formation of a receptor-proximal prosurvival com-
plex I (Micheau and Tschopp, 2003). In this complex, ubiquityla-
tion of receptor-interacting protein 1 (RIPK1) by the enzymes
TRAF2 (Alvarez et al., 2010), cIAP1, and cIAP2 (Bertrand et al.,908 Immunity 35, 908–918, December 23, 2011 ª2011 Elsevier Inc.2008; Varfolomeev et al., 2008) mediates the formation of a
platform involved in the activation of the transcription factor
NF-kB, which leads to induction of genes regulating cell survival,
immune activation, and inflammation (Karin, 2009). However, the
view of RIPK1 as an absolute requirement in TNF-induced NF-kB
activation has recently been challenged by the observation that
this pathway is only partially blocked in RIPK1-deficient mouse
embryonic fibroblasts (Wong et al., 2010), suggesting the exis-
tence of alternative signaling pathways, such as TNF-induced
NF-kB activation involving the linear ubiquitin chain assembly
complex (LUBAC) (Tokunaga et al., 2009). Despite these contro-
versies, it is obvious that RIPK1 is important in survival signaling
because RIPK1-deficient mice die within 3 days after birth as
a result of massive apoptosis of lymphoid and adipose tissue
(Kelliher et al., 1998).
Absence of RIPK1 ubiquitylation in TNFR1 complex I destabi-
lizes this complex (Hitomi et al., 2008), allowing the formation of
the cytosolic complex II, which signals to cell death (O’Donnell
et al., 2007; Wang et al., 2008). Formation of this complex, which
also recruits RIPK3 if expressed, results in caspase-8 activation
and induction of apoptosis (He et al., 2009). Caspase-8 can
cleave, and probably inactivate, both RIPK1 and RIPK3 (Feng
et al., 2007; Lin et al., 1999). Recently, it was found that RIPK1
interacts with RIPK3 forming a necrosis signaling complex (Cho
et al., 2009; He et al., 2009; Zhang et al., 2009), also called
necrosome (Vandenabeele et al., 2010). This RIPK1-RIPK3-
dependent necrosis can be induced by engagement of death
receptors (Holler et al., 2000; Vercammen et al., 1998b) either
directly or in conditions of caspase inhibition. RIPK1 kinase
activity is indispensable for TNF-induced necrosis but is
not required for NF-kB activation (Degterev et al., 2008; Lee
et al., 2004), and represents a form of regulated necrosis also
called necroptosis (Degterev et al., 2008). The discovery of
necrostatin-1 (Nec-1) as a RIPK1-specific kinase inhibitor
enabled selective inhibition of necroptosis and investigation of
its contribution to pathophysiological conditions (Degterev et al.,
2008). Altogether, these observations have discredited the
paradigm of necrosis as a mere accidental form of cell death
and strongly argue for the existence of a regulated form of
necrosis that can be specifically targeted just like apoptosis.
We investigated the role of apoptotic executioner caspases (cas-
pase-3 and -7), inflammatory caspase-1, and RIPK in TNF-
induced acute systemic inflammatory response syndrome
(SIRS), a mouse model of sterile sepsis (Tracey et al., 1986).
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Figure 1. Deletion of Executioner Caspases Does
Not Protect against TNF-Induced Necroptosis
In Vitro or Mortality In Vivo
(A) Differential effect of zVAD-fmk (10 mM) and knockdown
of caspases on mTNF-induced necroptosis in L929 cells.
Percentage of PI positive cells was analyzed on a
BDPathway 855 instrument.
(B) Combination of zVAD-fmk and knockdown of cas-
pases. Closed symbols designate combination with zVAD-
fmk. Percentage of PI positive cells was determined as
in (A).
(C) Knockdown efficiency was checked by immuno-
blotting.
(D) Body temperature and survival of WT (n = 8), Casp1/
(n = 5), Casp3/ (n = 5), and Casp7/ (n = 4) mice chal-
lenged with mTNF (9.5 mg, i.v.).
(E and F) Representative section of the ileum of WT (n = 2)
and Casp3/ (n = 2) mice 2 hr after mTNF injection was
analyzed by H&E staining (E) and TUNEL (F, pink, overlap
with DAPI; red, nonspecific staining of luminal content).
The original image ismagnified3200 in (D) and3100 in (E).
(G) WT (n = 5) and Casp3/ (n = 5) mice were challenged
with mTNF (9.5 mg, i.v.) and plasma levels of DAMPs and
cytokines were analyzed at 6 hr and compared to 0 hr
control mice (WT [n = 4] and Casp3/ [n = 4]). Error bars
represent SEM.
Immunity
RIPK1, RIPK3, and Necroptosis in SepsisSepsis is the leading cause of death in critically ill patients, and
TNF functions as a central mediator (Bone, 1992). The molecular
mechanism by which TNF causes SIRS remains unclear despite
elaborate in vitro studies on TNF signaling. In vivo, induction of
proinflammatory cytokines such as IL-1 (Everaerdt et al., 1994)
and IL-17 (Takahashi et al., 2008) partiallymediates TNF-induced
SIRS, suggesting that the gene induction pathway contributes to
the pathology. In contrast, the pan-caspase inhibitor zVAD-fmk
strongly sensitizes mice to the shock-inducing properties of
TNF, indicating that caspases have a protective role (Cauwels
et al., 2003). However, the precise mechanism underlying this
sensitization remains elusive.
We showed that RIPK3 deficiency or RIPK1 kinase inhibition
protects mice frommortality due to TNF-induced SIRS, whereasImmunity 35, 908–we excluded a role for apoptosis and inflamma-
some activity. Therefore, targeting the molec-
ular components of necroptosis is a promising
strategy for the treatment of these life-threat-
ening conditions.
RESULTS
RIPK1- and RIPK3-Dependent
Necroptosis in Cells Is Inhibited by
Caspase-8 but not by Caspase-3 and -7
Before examining the contribution of caspases
and RIPKs in TNF-mediated SIRS in vivo using
mutant mice, we characterized their precise
role in vitro using an siRNA approach. In L929
cells, TNF induces RIPK1-RIPK3-dependent
necroptosis without the need to add caspase-
inhibitors such as zVAD-fmk (Cho et al., 2009;
Degterev et al., 2008; He et al., 2009; Zhanget al., 2009). In agreement, we found that Nec-1 or RIPK3 knock-
down almost completely prevented TNF-induced necroptosis
(Figure S1 available online). As shown previously (Vercammen
et al., 1998a), necroptosis was enhanced by the pan-caspase
inhibitor zVAD-fmk (Figure 1A). Because of potential off-target
effects of zVAD-fmk (Vandenabeele et al., 2006), we tried to iden-
tify the exact target of its sensitizing effect. We speculated that
the primary target could be caspase-8, a component of signaling
complex II (Micheau and Tschopp, 2003), which can cleave
RIPK1 (Lin et al., 1999) and RIPK3 (Feng et al., 2007). Indeed,
specific knockdown of caspase-8 by siRNA, like zVAD-fmk,
strongly sensitized cells for TNF-induced necroptosis (Figure 1A).
The effect of caspase-8 knockdown in vitro is in agreement with
published findings in vivo (Kaiser et al., 2011; Oberst et al., 2011).918, December 23, 2011 ª2011 Elsevier Inc. 909
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Figure 2. Ripk3–/– Mice Are Protected against TNF-Induced SIRS
(A and B) Body temperature and survival of Ripk3/mice (A, n = 10; B, n = 15)
andWTmice (A, n = 14; B, n = 10) i.v. injected with two different doses of mTNF
(A, 5 mg; B, 9 mg). Cumulative results of three independent experiments are
shown.
(C) Body temperature and survival of Ripk3/mice (n = 5) andWTmice (n = 6)
injected with mTNF (9 mg, i.v.) after pretreatment with zVAD-fmk. **p < 0.001,
***p < 0.0001 versus WT mice. Error bars represent SEM (left panels).
Immunity
RIPK1, RIPK3, and Necroptosis in SepsisIn contrast, knockdown of executioner caspase-3 or -7, or their
combined knockdown, did not affect TNF-induced necroptosis
(Figure 1A). The fact that zVAD-fmk addition in caspase-8 knock-
down cells did not further sensitize to necroptosis, while it did
in case of caspase-3 or caspase-7 knockdown (Figure 1B),
demonstrates that the antinecroptotic function of caspases after
TNF stimulation is confined to caspase-8 and not performed by
the prototype apoptotic executioner caspases.
Apoptotic Executioner Caspases Do Not Contribute to
TNF-Induced SIRS but Prevent Associated Gut Damage
The above in vitro data prompted us to examine the role of
caspase-dependent apoptosis and RIPK-dependent necropto-
sis after TNF injection in vivo, which provokes a systemic inflam-
mation resembling clinical SIRS and sepsis (Tracey et al., 1986).
We previously demonstrated that inhibition of caspases by
zVAD-fmk strongly sensitizes mice to TNF-induced shock (Cau-
wels et al., 2003). To evaluate the contribution of apoptotic
executioner caspases, we used mice deficient in caspase-3
(Woo et al., 1998) or -7 (Figure S2). Although there is overlap in
the substrate specificities of these caspases (Demon et al.,
2009), the corresponding mutant (/) mice have distinct
phenotypes (Lamkanfi et al., 2007). We also used mice deficient
in inflammatory caspase-1, which mediates pyroptosis, yet
another form of cell death (Bergsbaken et al., 2009). Hypo-
thermia and mortality after TNF administration were comparable
in all groups of mice (Figure 1D), indicating that neither execu-
tioner caspases nor the inflammatory caspase-1 are major
targets of zVAD-fmk-mediated sensitization of TNF-induced
SIRS. Unfortunately, we could not study the role of caspase-8
in this sensitization in vivo because deletion of the caspase-8
gene in mice is embryonically lethal (Varfolomeev et al., 1998).
Intestinal damage accompanied by apoptosis and detach-
ment of intestinal epithelial cells (IECs) are typical features of
TNF-induced SIRS (Piguet et al., 1999; Tracey et al., 1986) and
are thought to be critically involved in SIRS pathology. Two
hours after TNF injection, WT mice showed swollen villi and an
increase in infiltrates (Figure 1E) and high level of TUNEL posi-
tivity (Figure 1F), which were almost absent in Casp3/ mice
(Figures 1E and 1F). Because tissue damage may result in
release of intracellular molecules such as the lysosomal enzyme
hexosaminidase (HEX) (Kuenzler et al., 2002) and cytosolic LDH,
we examined the activity of these enzymes in circulation.
Plasma activities of HEX and LDH increased in WT mice after
TNF injection, but despite protection against gut damage,
Casp3/ mice displayed similar amounts as WT (Figure 1G).
Accordingly, there was no difference in cytokine concentrations
(Figure 1G). Thus, caspase-3-dependent apoptosis, whichmight
occur also in tissues other than the gut, has no causal role in
lethal SIRS.
RIPK3 Gene Deletion Protects Mice against
TNF-Induced SIRS
To analyze the contribution of RIPK-dependent necrosis to SIRS
mortality, we focused on two key components of this pathway:
RIPK1 and RIPK3. Given that Ripk1 deletion causes postnatal
death (Kelliher et al., 1998), we used Ripk3/ mice, which are
viable and show no developmental or homeostatic abnormalities
(Newton et al., 2004). WT and Ripk3/ mice were challenged910 Immunity 35, 908–918, December 23, 2011 ª2011 Elsevier Inc.with two different doses of TNF; in both cases, all WT mice died
whereasRipk3/micewere protected from severe hypothermia
anddeath (Figures 2Aand2B). Because inhibition of caspases by
zVAD-fmk strongly sensitizes mice to the lethal effect of TNF
(Cauwels et al., 2003), we examined whether RIPK3 deficiency
could also provide protection in thismodel.Ripk3/mice recov-
ered from hypothermia and survived longer and at higher rates
(Figure 2C).Our results suggest that aRIPK3-dependent necrotic
pathway might be involved in TNF-induced SIRS regardless of
the absence or presence of caspase inhibition.
RIPK3-Deficient Mice Are Not Protected against Gut
Damage
Although deletion of Casp3 reduced IEC apoptotic cell death
(Figure 1F), it did not improve survival (Figure 1D). To analyze
the possible contribution of necrotic cell death to gut damage,
we compared the bowel pathology of WT and Ripk3/ mice.
Inflammatory features were evident 2 hr after TNF administration
in WT mice and persisted for up to 6 hr (Figure 3A). Ripk3/
mice, though they were protected from death, exhibited the
same severity of damage as WT mice both 2 and 6 hr after
TNF (Figure 3A). Also, the number of TUNEL-positive IECs was
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Figure 3. Tissue Damage andCell Death Are Different inRipk3–/– and
WT Mice
Organs of Ripk3/and WT mice (n = 5 per time point per genotype) were
dissected and fixed 0, 2, and 6 hr after mTNF injection (9 mg, i.v.). Represen-
tative pictures are shown. H&E (A) and TUNEL (B) staining of the ileum (pink,
overlap with DAPI; red, nonspecific staining of luminal content). Shown in (C) is
H&E staining of the liver shows focal necrotic cells at 2 hr in WT mice,
evidenced by pyknotic nuclei and eosinophilic cytoplasm (arrow). Red blood
cells in sinusoids are indicated by arrow heads. The original image is magnified
3200. Mice analyzed for each genotype; n = 3.
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RIPK1, RIPK3, and Necroptosis in Sepsissimilar in WT and Ripk3/ mice after TNF injection (Figure 3B),
whereas it was diminished in Casp3/ mice (Figure 1F). These
results show that RIPK3 is not involved in TNF-induced gut
damage during SIRS and indicate again that gut damage
does not contribute to mortality. In contrast, focal necrosis in
the liver of WT mice was already prominent 2 hr after TNF,
but was much milder in Ripk3/mice (Figure 3C). We conclude
that absence of RIPK3 selectively inhibits liver-associated
necrotic cell death but does not affect gut pathology caused
by apoptosis of IECs.IProtection of RIPK3-Deficient Mice Is Accompanied by
Reduction in Cell Death, Tissue Damage, and Sustained
Inflammation
During apoptosis cellular contents are largely contained in
apoptotic vesicles and cleared by phagocytosis, but during
necrosis cellular contents leak out due to rupture of the cell
membrane, and as a result damage-associated molecular
patterns (DAMPs) are released. The increase in plasma activity
of HEX and LDH was significantly lower in Ripk3/ mice than
in WT mice (Figure 4A), in striking contrast to Casp3/ mice,
which showed similar activities as WT mice (Figure 1G). The
same attenuated response was observed in Ripk3/ mice for
organ specific damage parameters such as AST and ALT (liver),
as well as creatine kinase (CK) (heart or kidney) (Figure 4A). In
patients with trauma, increased amounts of circulating mito-
chondrial DNA (mtDNA) could function as DAMPs after tissue
injury (Zhang et al., 2010). We tested three mitochondrial genes,
cytochrome B (mt-Cytb), Cytochrome C Oxidase III (mt-Co3),
and NADH dehydrogenase (mt-Nd1). All of them showed time-
dependent increases in plasma after TNF challenge in WT, but
not in Ripk3/ mice (Figure 4B). These results demonstrate
that cell death and tissue damage are prevented by RIPK3 defi-
ciency. Besides cell death-associated parameters, we evaluated
inflammatory gene induction by determining plasma concentra-
tions of proinflammatory cytokines. In WT mice, concentrations
of IL-6 and IL-1 after TNF injection increased dramatically with
time (Figure 4C), as reported earlier (Takahashi et al., 2008).
RIPK3 gene deletion had no effect on the plasma concentrations
of either cytokine early after TNF administration (2 hr). This
confirms earlier reports that RIPK3 is not directly involved in
TNF-mediated inflammatory signaling (Newton et al., 2004).
However, later on (6 hr), cytokine concentrations were signifi-
cantly lower in Ripk3/ mice (Figure 4C). Thus, the difference
in cell death parameters between Ripk3/ and WT mice
precedes the difference in cytokine concentrations (2 hr versus
6 hr) (Figures 4A and 4B compared to Figure 4C), suggesting
that the sustained cytokine increase in WT mice is an indirect
consequence of DAMP release rather than a direct consequence
of TNFR triggering. This also indicates that RIPK-dependent
necrosis induction, and not the transient inflammatory gene
induction pathway, is the key process in TNF-induced mortality.
Nec-1 Administration Prevents Mortality, Cell Death,
and Sustained Inflammation Associated with
TNF-Induced SIRS but Does Not Affect Gut Damage
To examine the involvement of RIPK1 in TNF-induced SIRS, we
pretreated mice with Nec-1. The effect of this pretreatment
resembled that of Ripk3 deletion: it significantly protected mice
from hypothermia and death caused by TNF (Figure 5A). Nec-1
also protected mice from hyperacute shock induced by the
combined administration of TNF and zVAD-fmk (Figure 5B).
Also, HEX and AST activities were reduced by Nec-1 pretreat-
ment (Figure 5C), indicating that necroptosis-mediated release
of lysosomal and cytosolic liver enzymes was prevented. Like
Ripk3 deletion, Nec-1 had no effect on early inflammation (2 hr)
as measured by plasma concentrations of IL-6 and IL-1 (Fig-
ure 5D), consistent with the observation that Nec-1 does not
affect TNF-induced NF-kB activation (Degterev et al., 2008).
However, 4 and 8 hr after TNF administration, cytokinemmunity 35, 908–918, December 23, 2011 ª2011 Elsevier Inc. 911
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Figure 4. Levels of DAMPs and Cytokines Are
Reduced in Ripk3–/– Mice
(A) Plasma samples of Ripk3/ and WT mice were
collected 0, 2, and 6 hr after challenge with mTNF (7.5 mg,
except for HEX: 9 mg, i.v.) and analyzed for activities of HEX
(n = 5 per time point per genotype), LDH, AST, ALT,
and CK.
(B) DNA was extracted from plasma samples of Ripk3/
and WT mice 0, 2, and 6 hr after mTNF challenge (7.5 mg,
i.v.). The relative abundance of mtDNA was determined by
Q-PCR for mt-Cytb, mt-Co3, and mt-Nd1. The samples
analyzed in (A) and (B) were either derived from onemouse
or pooled from two or three mice; the number of samples
per time point is indicated under the corresponding
columns.
(C) Plasma samples of Ripk3/ mice and WT mice
(n = 5 per time point per genotype) were collected 0, 2, and
6 hr after challenge with mTNF (9 mg, i.v.) and analyzed for
IL-6 and IL-1. *p < 0.05, **p < 0.01, ***p < 0.0001 versusWT
mice. Error bars represent SEM.
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RIPK1, RIPK3, and Necroptosis in Sepsisconcentrations were similar in Nec-1-treated mice (Figure 5D)
and Ripk3/ mice (Figure 4C) and significantly lower than in
WT mice. In line with the Ripk3/ results, intestinal damage
was comparable in control and Nec-1-treated mice (Figure 5E),
although the latter showed reduced liver tissue damage (Fig-
ure 5F). These results confirm that gut damage during TNF-
induced SIRS ismainlymediated by apoptosis, which apparently
does not contribute to lethal SIRS. On the contrary, RIPK1 kinase
activity in concert with RIPK3 is crucial, supporting a major role
for RIPK-mediated necrosis (or necroptosis) in the lethal
outcome.
RIPK3 Gene Deletion Protects Mice against Cecal
Ligation and Puncture
TNF is undoubtedly a central mediator of acute hyperinflamma-
tory sepsis. However, sepsis patients who survive the early
stages often develop hypoinflammatory sepsis and die from
primary or secondary infection (Hotchkiss and Karl, 2003). To912 Immunity 35, 908–918, December 23, 2011 ª2011 Elsevier Inc.confirm our findings in a more clinically relevant
setting, we used the cecal ligation and puncture
(CLP) model, which includes a microbial com-
ponent (Rittirsch et al., 2009). We performed
a mild CLP on Ripk3/ mice and age- and
sex-matched WT controls with a 22G needle.
Hypothermia caused by CLP was biphasic in
WT mice: after the initial acute hypothermia,
body temperature started to recover but then
gradually dropped again (Figure 6A). In contrast,
recovery from the initial hypothermia inRipk3/
mice was not followed by a second drop in tem-
perature and the body temperature of Ripk3/
mice was significantly higher than that of WT
mice throughout the experiment. In WT mice,
mortality rate gradually increased after the first
death occurrence at 40 hr, and eventually
42.1% of the mice died (Figure 6B). Onset of
mortality was significantly delayed in Ripk3/
mice and the majority of mice survived (85.7%)(Figure 6B). We then tested a more severe CLP condition with
a larger needle. In this condition, hypothermia in WT mice was
more profound (Figure 6C). Ripk3/mice underwent initial tran-
sient hypothermia, but their body temperature remained signifi-
cantly higher than that of WT mice (Figure 6C). Also in terms of
mortality,Ripk3/mice were significantly protected (Figure 6D).
Comparable bacteremia was detected at 10 and 26 hr after CLP
in both WT and Ripk3/ mice (Figure 6E). At 26 hr after CLP,
some mice in each genotype had increased bacteremia
whereas others had less as compared to the level at 10 hr, indi-
cating that there was no difference in the capacity to clear infec-
tion. In addition, there was a consistent tendency of reduced
DAMP and cytokine levels in plasma ofRipk3/mice at the later
time point, and LDH levels were significantly lower in Ripk3/
mice (Figures 6F and 6G). Therefore, we conclude that Ripk3
deletion also significantly protects mice in the CLP model
of sepsis, demonstrating a crucial role for RIPK3 in sepsis-
mediated mortality.
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Figure 5. Inhibition of RIPK1 Kinase Activity
Protects against TNF-Induced SIRS
(A) Body temperature (means ± SEM) and survival of WT
mice (n = 6) injected with mTNF (9.5 mg, i.v.) after
pretreatment with Nec-1. Control mice (Ctrl, n = 6)
received an equal amount of vehicle before the mTNF
challenge. A representative result from three experiments
is shown.
(B) Body temperature (means ± SEM) and survival of WT
mice (n = 6) injected with mTNF (9.5 mg, i.v.) after
pretreatment with Nec-1 and zVAD-fmk. Control mice
(n = 6) received an equal amount of vehicle and zVAD-fmk
before the mTNF challenge. A representative result of
three experiments is shown.
(C and D) Levels of HEX and AST (C), IL-6, and IL-1 (D)
in plasma samples of WT mice (n = 4) injected with mTNF
(9.5 mg, i.v.) after pretreatment with Nec-1 or vehicle.
*p < 0.05, **p < 0.01, and ***p < 0.0001 versus controlmice.
Error bars represent SEM.
(E and F) H&E staining of the ileum (E) and liver (F) 8 hr after
mTNF injection of Nec-1 pretreatedmice and controlmice.
The original image is magnified 3400. Mice analyzed for
each group; n = 3.
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The recent discovery of RIPK-dependent necrosis or necropto-
sis as a tightly regulated pathway brought new insight into the
molecular mechanisms governing cell death and survival
(Declercq et al., 2009), as well as into the crosstalk between
different cell death modalities. We discovered earlier that inhibi-
tion of caspases in cells overexpressing CrmA (a caspase-8
inhibitor) sensitized them to TNF-induced necrosis (Vercammen
et al., 1998a), suggesting that specifically caspase-8 inhibits
necroptosis. The mechanism is not completely clear yet, but it
probably involves caspase-8-dependent cleavage of RIPK1
(Lin et al., 1999) and/or RIPK3 (Feng et al., 2007). Deficiency of
FADD, the adaptor of caspase-8, also enhanced necroptotic
sensitivity (Holler et al., 2000; Osborn et al., 2010; Zhang et al.,
2011). In addition, four recent reports demonstrate that this
negative regulation of necroptosis by FADD and caspase-8
also operates in vivo (Kaiser et al., 2011; Oberst et al., 2011;
Welz et al., 2011; Zhang et al., 2011). Interestingly, we reported
previously that coadministration of zVAD-fmk sensitizes mice
to TNF-induced SIRS (Cauwels et al., 2003), suggesting thatImmunity 35, 908–a necroptotic pathway might contribute to this
pathology. In the current study, we examined
the role of apoptotic executioner caspases
(caspase-3 and -7), the inflammatory caspase-1,
and necroptosis-inducing kinases (RIPK1 and
RIPK3) in a cellularmodel and in an in vivomouse
model of TNF-induced toxicity. In the cellular
model, zVAD-fmk or knockdown of caspase-8,
but not of caspase-3 or -7, strongly accelerated
TNF-induced necroptosis. In the absence of
caspase-8, zVAD-fmk did not exert a further
sensitizing effect, demonstrating that addition
of zVAD-fmksensitizes for necroptosisby target-
ing caspase-8. These in vitro results are in line
with the recent reports on the in vivo role ofcaspase-8 as a physiological inhibitor of RIPK3-mediated nec-
roptosis (Kaiser et al., 2011; Oberst et al., 2011). Because of
embryonic lethality of caspase-8 deficiency (Varfolomeev et al.,
1998), we could not test the consequences of caspase-8 deletion
in our SIRSmodel. Depletion of neither the executioner caspases
nor caspase-1 had any effect in the cellular model or in TNF-
induced SIRS, ruling out involvement of caspase-dependent
apoptosis and caspase-1-mediated inflammation and/or pyrop-
tosis. Caspase-1, which is involved in maturation and secretion
of IL-1b and IL-18, has been implicated in endotoxemia (Saleh
et al., 2006) but apparently not in TNF-induced SIRS. Earlier
results using an IL-1 receptor antagonist (Everaerdt et al., 1994)
pointed to a role for IL-1a, which can function as an alarmin
released from necrotic cells (Cohen et al., 2010).
The model of TNF-induced SIRS mimics the acute hyperin-
flammatory phase of SIRS, which is thought to be driven by
a proinflammatory ‘‘cytokine storm’’ (Hotchkiss and Nicholson,
2006). Here, by using both genetic and drug-based approaches,
we revealed a decisive role for RIPK1 and RIPK3 in determining
life or death during this hyperinflammatory phase of SIRS. As
RIPK1 kinase activity can also induce apoptosis in certain918, December 23, 2011 ª2011 Elsevier Inc. 913
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Figure 6. RIPK3 Deletion Protects against
CLP-Induced SIRS/Sepsis
WT (n = 21) and Ripk3/ mice (n = 14) were sub-
jected to mild CLP as described in materials and
methods and monitored for body temperature
(A) and mortality (B). Sham operated mice (SOP)
(n = 6) underwent surgery without CLP. Cumulative
results of two independent experiments are
shown. In another experiment WT (n = 12) and
Ripk3/ mice (n = 7) were subjected to more
severe CLP and body temperature (C) and mor-
tality (D) were monitored. Two independent ex-
periments were merged. Another CLP experiment
was performed with the severe condition, and
blood samples were collected from WT (n = 7)
and Ripk3/ mice (n = 7) for the analysis of
bacteremia (E), DAMPs (F), and cytokines (G);
***p < 0.0001, *p < 0.05. Means ± SEM in (A), (C),
(F), and (G).
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RIPK1, RIPK3, and Necroptosis in Sepsisconditions such as depletion of IAPs (Vandenabeele et al., 2010;
Wang et al., 2008), Nec-1 might also target some types of
apoptosis in vivo. However, RIPK3 deficiency does not affect
apoptosis but only regulated necrosis (Cho et al., 2009; He
et al., 2009; Zhang et al., 2009), and given that Ripk3/ mice
are protected against SIRS, our data strongly support the notion
that Nec-1 targets RIPK1-mediated necroptosis in TNF-induced
SIRS. The results obtained in Ripk3/ mice suggest the para-
mount importance of necroptosis as an initial ‘‘cell death storm’’
that could lead to acute or sustained inflammation. Our data
challenge the generally held view that direct proinflammatory
cytokine induction by TNF is the major cause of the unrestrained
immune response and the mortality of acute SIRS (Ulloa and
Tracey, 2005). In agreement with earlier reports (Degterev
et al., 2008; Lee et al., 2004; Newton et al., 2004), neither inhibi-914 Immunity 35, 908–918, December 23, 2011 ª2011 Elsevier Inc.tion of RIPK1 kinase activity nor absence
of RIPK3 affected the transient cytokine
induction, but as we demonstrate in this
paper they strongly reduced the sus-
tained cytokine response. Importantly,
reduction in this sustained cytokine re-
sponse was associated with reduced
mortality. Therefore, it is conceivable
that a synergistic combination of multiple
DAMPs released by necroptotic cells
might trigger sustained cytokine release
and amplify the inflammatory response.
DAMPs, such as mitochondrial factors,
high-mobility group box 1 (HMGB1),
heat shock proteins, uric acid, ATP, and
extracellular matrix proteins can be re-
leased from necrotic cells or damaged
tissue and trigger or sensitize pattern
recognition receptors (PRRs) mediating a
sterile inflammation (Chen and Nun˜ez,
2010; Krysko et al., 2011). HMGB1 (Lotze
and Tracey, 2005), histone (Xu et al.,
2009), and mtDNAs (Zhang et al., 2010)
are found in the plasma of sepsis or
trauma patients and were shown toprovoke inflammation. We indeed detected DAMPs such as
mtDNA and intracellular proteins such as AST, ALT, LDH, and
HEX in circulation, pointing to similar mechanisms. Which
PRRs are responsible for the sustained cytokine wave in our
model is still to be resolved. Currently, we cannot formally prove
that necrotic cell death can ignite SIRS. Such a proof of concept
may require different approaches such as introducing necrop-
totic cells in circulation. In addition, we observed that liver-
associated necrotic cell death is reduced by Ripk3 deletion
and by Nec-1 pretreatment of WT mice, indicating that liver
damage might contribute to TNF mortality. In contrast, intestinal
damage seems to be caused mainly by apoptosis and is not
related to mortality in TNF-induced SIRS. The apparent tissue
specificity in cell death modality warrants further investigation.
A recent paper showed enhanced RIPK3-dependent necrosis
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RIPK1, RIPK3, and Necroptosis in Sepsisof IECs upon loss of FADD (Welz et al., 2011). This correlated
with increased RIPK3 levels, which has previously been shown
to influence the sensitivity of cells and tissues to necrosis (Cho
et al., 2009; He et al., 2009). Hence, the expression of several
necrosis-regulating components, including RIPK1, RIPK3,
FADD, caspase-8, cIAPs, and CYLD, might determine the cell’s
predisposition to either cell death mode. Ripk3/ mice are not
protected against an acute hepatitis model induced by the
combination of LPS and galactosamine (Kaiser et al., 2011). In
this model, however, inhibition of liver protein synthesis shifts
cell death mode to apoptosis, given that Casp8 deletion or
zVAD-fmk treatment conferred protection (Jaeschke et al.,
1998; Kaiser et al., 2011).
We demonstrated that the protection provided by RIPK3 gene
ablation holds true in a septic model of SIRS, namely CLP. This
model closely resembles the clinical SIRS that develops after
peritonitis (Baker et al., 1983; Rittirsch et al., 2009) and is more
relevant for clinical conditions, which often involve both hyperin-
flammatory and hypoinflammatory phases (Hotchkiss and Karl,
2003). In the hypoinflammatory phase of sepsis, excessive apo-
ptosis of lymphocytes compromises immune defenses, which
contributes to exacerbation of primary or secondary infection
(Hotchkiss et al., 2005). As inhibition of necroptosis does not
affect apoptosis or NF-kB activation in cellular models (Degterev
et al., 2008; Degterev et al., 2005), our results show that targeting
necroptosis could be clinically relevant. Although the exact
role of TNF in CLP is unclear (Echtenacher et al., 1990; Leon
et al., 1998), our results strongly suggest that RIPK-dependent
necrosis is the common denominator between the sterile SIRS
and septic CLP models.
So far, RIPK-mediated necroptosis has been identified
in several experimental conditions: ischemia-reperfusion injury
(Degterev et al., 2005), cerulein-induced acute pancreatitis (He
et al., 2009; Zhang et al., 2009), viral infection (Cho et al.,
2009), retinal detachment-induced photoreceptor necrosis
(Trichonas et al., 2010), and skin (Bonnet et al., 2011) and intes-
tinal inflammation (Gu¨nther et al., 2011; Welz et al., 2011). We
now add SIRS and sepsis to this list and identify RIPK1 and
RIPK3 as potential therapeutic targets for the treatment of this
life-threatening condition. These findings challenge an earlier
view emphasizing the ‘‘cytokine storm’’ as driving force in
SIRS and sepsis and present a therapeutic option of targeting
necroptosis as an alternative to an anticytokine (or anti-inflam-
matory) therapy. The efficacy of Nec-1 indeed provides a proof
of concept for targeting necroptosis-associated mortality
without compromising immune responses, which renders the
patients more susceptible to life-threatening infection (Fisher
et al., 1996). The differential requirement of RIPK1 kinase activity
for gene induction and necroptosis in response to TNF makes it
possible to inhibit necroptosis while keeping RIPK1-mediated
immune functions intact during sepsis and in any other disease
involving TNF. The protective effect of RIPK3 deletion in the
CLP model without compromising immune function against
systemic bacteremia provides strong support for this hypoth-
esis. New knowledge on the precise regulatory mechanisms of
necrosome formation, the molecular interactions involved, and
the pathways downstream of RIPK1 and RIPK3 kinase activity
will provide additional targets for intervention in these high
mortality pathological conditions, which have previously beenIclassified as uncontrollable. These pathologies include sepsis,
trauma, pancreatitis, ischemia-reperfusion injury, transplant
injury, burns, and toxin- or drug-induced adverse reactions
such as toxic epidermal necrolysis.
EXPERIMENTAL PROCEDURES
Cells, Cytokines, and Reagents
L929sAhFas cells were generated as previously described (Vercammen et al.,
1998b) and are referred to as L929 cells throughout this paper. Cells were
cultured in Dulbecco’s modified Eagle’smedium supplemented with 10% fetal
calf serum, penicillin (100 IU/ml), streptomycin (0.1 mg/ml), and L-glutamine
(0.03%). Recombinantmouse TNF (mTNF) was produced inE. coli and purified
in our laboratories. Activity of the mTNF used in vivo, determined by MTT
assay, was 1.7 3 108 IU/mg. Endotoxin contamination, measured by the
Limulus amebocyte lysate (LAL) assay (Kabivitrium), was 0.47 EU/mg. Activity
of the mTNF used in vitro was 3.33 108 IU/mg. Nec-1 and zVAD-fmk were dis-
solved in DMSO and diluted in medium or PBS. The following antibodies were
used: anti-murine caspase-3 and -7 (rabbit polyclonal antibodies made in-
house), anti-caspase-8 (1G-12) (Alexis Biochemicals, San Diego, CA), anti-
RIPK3 (Sigma Aldrich), and anti-b-tubulin (HRP) (Abcam, Cambridge, UK).
RNAi-Mediated Knockdown
L929sAhFas cells were transfected in accordance with the manufacturer’s
protocol using specific siRNAs and siCONTROLnontargeting siRNAasa nega-
tive control (ON-TARGETplus SMART pool siRNA; Dharmacon, Thermo Fisher
Scientific,Waltham,MA, USA). INTERFERin (Polyplus-transfection SA, Illkirch,
France) was used as a transfection reagent. Cell death assays were performed
72 hr after transfection.
Mice
C57BL/6J WT mice matched for gender and age were either purchased from
Janvier (Le Genest, France) or bred in our own facility. There was no difference
in TNF sensitivity between WT mice from different sources. Ripk3/ mice,
produced by targeted gene deletion (Newton et al., 2004), were a kind gift
from V. Dixit (Genentech, San Francisco). Casp3/ mice were a kind gift
from T. Mak (Woo et al., 1998) (The Campbell Family Cancer Research
Institute, Toronto, Canada). Casp7/ mice were produced by targeted gene
deletion in our facility (Figure S2). All knockout mice were backcrossed to
C57BL/6 background for more than ten generations and bred at the VIB
Department for Molecular Biomedical Research in either specific-pathogen-
free or conventional animal facilities. Mice were used at the age of 8–14weeks.
All experiments on mice were conducted according to institutional, national,
and European regulations. Animal protocols were approved by the ethics
committee of Ghent University.
Injections, Monitoring, and Sampling
mTNF and inhibitors were diluted in endotoxin-free PBS and injected in
a volume of 0.2ml. Nec-1 andmTNFwere injected intravenously (i.v.), whereas
zVAD-fmk was injected intraperitoneally (i.p.). Nec-1 (125 mg) was given 17min
before mTNF injection. zVAD-fmk was given 15 min before (250 mg) and 1 hr
after (100 mg) mTNF. Rectal body temperature was recorded with an electric
thermometer (model 2001; Comark Electronics). Plasma samples and tissue
samples of ileum and liver were collected at designated times after injection.
Blood was obtained by cardiac puncture.
CLP Procedure and Blood Culture
TheCLP procedurewas performed in accordancewith the guidelines (Rittirsch
et al., 2009). Detailed procedure is described in the Supplemental Information.
Determination of DAMPs and Cytokines
HEX activity wasmeasured as described (Kuenzler et al., 2002). Levels of AST/
ALT and LDH were determined by an automated clinical analyzer. DNA was
extracted from plasma samples with a DNA Blood mini kit (QIAGEN, Hilden,
Germany) and mtDNA levels were determined by Q-PCR as described (Zhang
et al., 2010). Plasma cytokine levels were determined with bioassay or milliplex
(Millipore) as described in the Supplemental Information.mmunity 35, 908–918, December 23, 2011 ª2011 Elsevier Inc. 915
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Histopathology was evaluated on paraffin sections. Apoptosis was identified
by the terminal deoxynucleotidyl-transferase-mediated deoxyuridine tri-
phosphate nick-end labeling technique (TUNEL; Fluorescein In Situ Cell
Death Detection Kit; Roche Diagnostic, Mannheim, Germany) in accordance
with the manufacturer’s instructions. Sections were counterstained with
DAPI.
Statistical Analysis
Statistical analysis was performed with Prism software (GraphPad Software,
Inc.). Body temperature and plasma factor levels are shown as means ±
SEM and compared with one-way analysis of variance (ANOVA) test with
Bonferroni posttest. Survival curves were compared using log-rank Mantel-
Cox test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes two figures and Supplemental Experi-
mental Procedures and can be found with this article online at doi:10.1016/
j.immuni.2011.09.020.
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